G Pizzorno

680 total citations
19 papers, 558 citations indexed

About

G Pizzorno is a scholar working on Molecular Biology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, G Pizzorno has authored 19 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Oncology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in G Pizzorno's work include Biochemical and Molecular Research (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Acute Lymphoblastic Leukemia research (4 papers). G Pizzorno is often cited by papers focused on Biochemical and Molecular Research (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Acute Lymphoblastic Leukemia research (4 papers). G Pizzorno collaborates with scholars based in United States and Italy. G Pizzorno's co-authors include Robert E. Handschumacher, Arlene R. Cashmore, Barbara A. Moroson, G. Peter Beardsley, Menghan Liu, Rosalind L. Russell, Deliang Cao, P Periti, Teresita Mazzei and John J. McGuire and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical Pharmacology and Stem Cells.

In The Last Decade

G Pizzorno

19 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G Pizzorno United States 13 301 199 100 73 67 19 558
William Gibson United Kingdom 15 314 1.0× 239 1.2× 96 1.0× 43 0.6× 18 0.3× 23 660
Robert Bartlett Germany 10 180 0.6× 101 0.5× 80 0.8× 37 0.5× 84 1.3× 12 672
Carole Ferraro France 5 160 0.5× 83 0.4× 116 1.2× 72 1.0× 46 0.7× 5 510
K Német Hungary 6 231 0.8× 185 0.9× 45 0.5× 32 0.4× 26 0.4× 12 692
Kamran Gharehbaghi Austria 13 328 1.1× 127 0.6× 53 0.5× 50 0.7× 121 1.8× 25 675
Taina Jaatinen Finland 17 332 1.1× 105 0.5× 42 0.4× 35 0.5× 33 0.5× 28 750
Elizabeth A. Rayl United States 4 280 0.9× 272 1.4× 67 0.7× 48 0.7× 41 0.6× 4 615
Paul H. Fischer United States 12 289 1.0× 259 1.3× 17 0.2× 30 0.4× 64 1.0× 26 540
S. D. Perova Russia 5 227 0.8× 126 0.6× 36 0.4× 41 0.6× 146 2.2× 8 728
Robert N. McEwan United States 15 436 1.4× 101 0.5× 34 0.3× 30 0.4× 42 0.6× 20 811

Countries citing papers authored by G Pizzorno

Since Specialization
Citations

This map shows the geographic impact of G Pizzorno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Pizzorno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Pizzorno more than expected).

Fields of papers citing papers by G Pizzorno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Pizzorno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Pizzorno. The network helps show where G Pizzorno may publish in the future.

Co-authorship network of co-authors of G Pizzorno

This figure shows the co-authorship network connecting the top 25 collaborators of G Pizzorno. A scholar is included among the top collaborators of G Pizzorno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Pizzorno. G Pizzorno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Fu, Siqing, F. García‐Sánchez, Injae Chung, et al.. (2009). Results of retroviral and adenoviral approaches to cancer gene therapy. Stem Cells. 16(S2). 247–250. 10 indexed citations
2.
Burtness, Barbara, et al.. (2001). A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.. PubMed. 6(5). 309–15. 6 indexed citations
3.
Cao, Dandan, Manjunath Nimmakayalu, Fu Wang, et al.. (1999). Genomic structure, chromosomal mapping, and promoter region analysis of murine uridine phosphorylase gene.. PubMed. 59(19). 4997–5001. 12 indexed citations
4.
Liu, Menghan, Deliang Cao, Rosalind L. Russell, Robert E. Handschumacher, & G Pizzorno. (1998). Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors.. PubMed. 58(23). 5418–24. 55 indexed citations
5.
Pizzorno, G, Lorrin Yee, Barbara Burtness, et al.. (1998). Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.. PubMed. 4(5). 1165–75. 35 indexed citations
6.
Murren, John R., Shannon W. Anderson, G Pizzorno, et al.. (1997). Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.. Journal of Clinical Oncology. 15(1). 148–157. 35 indexed citations
7.
Chambers, Suzanne K., J.T. Chambers, Carol A. Davis, et al.. (1997). Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.. Journal of Clinical Oncology. 15(5). 1945–1952. 12 indexed citations
8.
Pizzorno, G, et al.. (1997). The use of chemotherapy resistance in cancer treatment.. PubMed. 3(2). 60–9. 4 indexed citations
9.
Schwab, J C, et al.. (1995). Toxoplasma gondii tachyzoites possess an unusual plasma membrane adenosine transporter. Molecular and Biochemical Parasitology. 70(1-2). 59–69. 45 indexed citations
10.
Pizzorno, G & Robert E. Handschumacher. (1995). Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochemical Pharmacology. 49(4). 559–565. 18 indexed citations
11.
Pizzorno, G, Barbara A. Moroson, Arlene R. Cashmore, et al.. (1995). Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.. PubMed. 55(3). 566–73. 55 indexed citations
12.
Pizzorno, G, et al.. (1995). Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochemical Pharmacology. 49(4). 553–557. 31 indexed citations
13.
Ravikumar, T.S., G Pizzorno, John C. Marsh, et al.. (1994). Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors.. Journal of Clinical Oncology. 12(12). 2723–2736. 58 indexed citations
14.
Pizzorno, G, et al.. (1992). Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.. PubMed. 52(7). 1660–5. 23 indexed citations
15.
Pizzorno, G, Barbara A. Moroson, Arlene R. Cashmore, & G. Peter Beardsley. (1991). (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.. PubMed. 51(9). 2291–5. 21 indexed citations
16.
Pizzorno, G, et al.. (1991). Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines.. Molecular Pharmacology. 39(1). 85–89. 35 indexed citations
17.
Bertino, Joseph R., Julian Lin, G Pizzorno, Wei Wei Li, & Yu Chang. (1989). The basis for intrinsic drug resistance or sensitivity to methotrexate. Advances in Enzyme Regulation. 29. 277–285. 7 indexed citations
18.
Mini, Enrico, G Pizzorno, Marcella Coronnello, et al.. (1988). Impaired methotrexate polyglutamylation in a human leukemia cell line resistant to short-term, high-dose methotrexate. Pharmacological Research Communications. 20(5). 445–446. 3 indexed citations
19.
Pizzorno, G, Enrico Mini, Marcella Coronnello, et al.. (1988). Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.. PubMed. 48(8). 2149–55. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026